3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%

In This Article:

In the midst of geopolitical tensions and fluctuating market indices, the U.S. stock market is experiencing a cautious sentiment as investors react to recent earnings reports and global developments. Despite these uncertainties, opportunities may arise for discerning investors who focus on identifying stocks that are potentially undervalued, offering a chance to invest in companies trading at significant discounts relative to their intrinsic value.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name

Current Price

Fair Value (Est)

Discount (Est)

First National (NasdaqCM:FXNC)

$23.30

$46.25

49.6%

Capital Bancorp (NasdaqGS:CBNK)

$27.37

$53.44

48.8%

West Bancorporation (NasdaqGS:WTBA)

$23.58

$46.82

49.6%

Business First Bancshares (NasdaqGS:BFST)

$28.12

$55.07

48.9%

Five Star Bancorp (NasdaqGS:FSBC)

$32.35

$63.87

49.4%

Afya (NasdaqGS:AFYA)

$16.43

$31.50

47.8%

Datadog (NasdaqGS:DDOG)

$125.97

$243.25

48.2%

Advanced Energy Industries (NasdaqGS:AEIS)

$109.84

$219.25

49.9%

WEX (NYSE:WEX)

$178.01

$345.87

48.5%

Marcus & Millichap (NYSE:MMI)

$40.84

$78.74

48.1%

Click here to see the full list of 197 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

ChromaDex

Overview: ChromaDex Corporation is a bioscience company that develops healthy aging products and has a market cap of $522.07 million.

Operations: ChromaDex's revenue is primarily derived from its Consumer Products segment at $71.72 million, followed by Ingredients at $16.95 million, and Analytical Reference Standards and Services at $3.00 million.

Estimated Discount To Fair Value: 13%

ChromaDex's recent profitability and revenue growth, highlighted by a Q3 sales increase to US$25.58 million, underscore its potential as an undervalued stock based on cash flows. Trading at US$7.27, it is below the estimated fair value of US$8.35, reflecting a 13% discount. The company's strategic expansion with Niagen IV enhances its market position and supports projected earnings growth of over 80% annually, outpacing broader market expectations for both revenue and profit growth.

NasdaqCM:CDXC Discounted Cash Flow as at Nov 2024
NasdaqCM:CDXC Discounted Cash Flow as at Nov 2024

Bowhead Specialty Holdings

Overview: Bowhead Specialty Holdings Inc. offers specialty property and casualty insurance products in the United States and has a market cap of approximately $1.10 billion.

Operations: The company's revenue is derived from its specialty property and casualty insurance segment, totaling $389.14 million.